


In the Claims

Amend the claims as follows:

1(Currently Amended). A compound represented by Formula (I)



(I)


or a pharmaceutically acceptable salt, or N-oxide, thereof, wherein

R¹ is

- (a) hydrogen,
- (b) C₁-C₆-alkyl,
- (c) halogen;

R² is

- (a) hydrogen,
- (b) C₁-C₆-alkyl, optionally substituted with one or more of halogen, -OH, or aryl,
- (c) cycloalkyl,
- (d) CF₃,
- (e) aryl, optionally substituted with one or more of halogen or alkyl,
- (f) heteroaryl, optionally substituted with one or more of alkyl or halogen;



R^c is selected from hydrogen and C_{1-4} alkyl, wherein alkyl is optionally substituted with one or more of halogen or -OH;

n and m are independently 0, 1, 2, 3 or 4, provided that $n + m = 2, 3$ or 4;

q is 1 or 2; and

R^4 is hydrogen or halogen.

2(Original). The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

R^2 is optionally substituted C_1 - C_6 -alkyl.

3(Original). The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

R^2 is cycloalkyl.

4(Original). The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

R^2 is CF_3 .


5(Original). The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

R^2 is optionally substituted aryl.


6(Original). The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

R^2 is optionally substituted heteroaryl.


7(Original). The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein




8(Original). The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein




9(Original). The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein




10(Original). The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein



11(Original). The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein



12(Original). The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein



13(Original). The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

R^3 is piperidinyl.

14(Original). The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

R^3 is [(C₁₋₄) alkyl]piperidinyl.

15(Original). The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

R^3 is piperidin-4-yl.

16(Original). The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

R^3 is [(C₁₋₄) alkyl]piperidin-4-yl.

17(Original). The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

R^3 is 1-methylpiperidinyl.

18(Original). The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

R³ is 1-methylpiperidin-4-yl.


19(Original). The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

R³ is 1-(3-hydroxypropyl)-4-piperidinyl.

20(Original). The compound of Claim 1, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

R³ is 1-(3-hydroxyethyl)-4-piperidinyl.

21(Currently Amended). A compound represented by Formula (II)



(II)


or a pharmaceutically acceptable salt, or N-oxide, thereof, wherein

Het is pyridyl, pyridazinyl, triazinyl, thiazolyl, or isothiazolyl ~~heteroaryl~~, optionally substituted with one or more of amino, alkyl or halogen; and

~~R¹ and R³ each is as defined in Claim 1~~

R¹ is

- (d) hydrogen,
- (e) C₁-C₆-alkyl,
- (f) halogen;



R^c is selected from hydrogen and C_{1-4} alkyl, wherein alkyl is optionally substituted with one or more of halogen or -OH;

n and m are independently 0, 1, 2, 3 or 4, provided that $n + m = 2, 3$ or 4; and

q is 1 or 2.

22 (Original). The compound of Claim 21, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

Het is pyridyl.

23(Original). The compound of Claim 21, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

Het is pyridazinyl.

24(Original). The compound of Claim 21, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

Het is triazinyl.


25(Original). The compound of Claim 21, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein


Het is thiazolyl.

26(Original). The compound of Claim 21, or a pharmaceutically acceptable salt, or an N-oxide thereof, wherein

Het is isothiazolyl.

27(Original). A compound represented by





or a pharmaceutically acceptable salt, or an N-oxide thereof.

28 (Currently Amended). A method for controlling coccidiosis in poultry which comprises administering to said poultry a therapeutically effective amount, ~~or a prophylactically effective amount,~~ of a compound of Claim 1.

29. Cancel.

30. Cancel.

31. Cancel.

32 (Currently Amended). A composition ~~for controlling coccidiosis~~ which comprises a compound of Claim 1 and a pharmaceutically acceptable carrier.

33(Original). The composition of Claim 32 further comprising a second anticoccidial agent.

34(Original). The composition of Claim 33 wherein said second anticoccidial agent is selected from the group consisting of amprolium, ethopabate, clopidol, meticlorpindol, decoquinate, dinitolmide, halofuginone, lasalocid, maduramicin, monensin, narasin, nicarbazin, chlortetracycline, oxytetracycline, robenidine, salinomycin, semduramicin, and diclazuril.

35(Original). The composition of Claim 33 wherein said second anticoccidial agent is selected from the group consisting of amprolium, ethopabate, lasalocid, monensin, salinomycin, and diclazuril.

36(Original). The composition of Claim 32 wherein said carrier is poultry feedstuff.

37(Original). The composition of Claim 36 further comprising a second coccidial agent.

38(Original). The composition of Claim 37 wherein said second anticoccidial agent is selected from the group consisting of amprolium, ethopabate, clopidol, meticlorpindol, decoquinate, dinitolmide, halofuginone, lasalocid, maduramicin, monensin, narasin, nicarbazin, chlortetracycline, oxytetracycline, robenidine, salinomycin, semduramicin, and diclazuril.

39(Original). The composition of Claim 37 wherein said second anticoccidial agent is selected from the group consisting of amprolium, ethopabate, lasalocid, monensin, salinomycin, and diclazuril.

40(Original). The composition of Claim 32 wherein said carrier is poultry feed premix.

41(Original). The composition of Claim 40 further comprising a second anticoccidial agent.

42(Original). The composition of Claim 41 wherein said second anticoccidial agent is selected from the group consisting of amprolium, ethopabate, clopidol, meticlorpindol, decoquinate, dinitolmide, halofuginone, lasalocid, maduramicin, monensin, narasin, nicarbazin, chlortetracycline, oxytetracycline, robenidine, salinomycin, semduramicin, and diclazuril.

43(Original). A composition of Claim 41 wherein said second anticoccidial agent is selected from the group consisting of amprolium, ethopabate, lasalocid, monensin, salinomycin, and diclazuril.

44. Cancel.

45 (Currently Amended). A method for controlling malaria in a mammalian patient which comprises administering to said patient a therapeutically effective amount, ~~or a prophylactically effective amount,~~ of the compound of Claim 1.

46. Cancel.

47(Currently Amended). A method for controlling African trypanosomiasis in a mammalian patient which comprises administering to said patient a therapeutically effective amount, ~~or a prophylactically effective amount,~~ of a compound of Claim 1.

48. Cancel.

49(Currently Amended). A method for controlling Chagas disease in a mammalian patient which comprises administering to said patient a therapeutically effective amount, ~~or a prophylactically effective amount,~~ of a compound of Claim 1.

50 (Currently Amended). A method for controlling toxoplasmosis in a mammalian patient which comprises administering to said patient a therapeutically effective amount, ~~or a prophylactically effective amount,~~ of a compound of Claim 1.

51. Cancel.

52(Currently Amended). A method for controlling coccidiosis in poultry which comprises administering to said poultry a therapeutically effective amount, ~~or a prophylactically effective amount,~~ of a compound of Claim 21.

53(Currently Amended). A method for controlling coccidiosis in poultry which comprises administering to said poultry a therapeutically effective amount, ~~or a prophylactically effective amount,~~ of a combination of anticoccidial agents comprising a compound of Claim 21 and a second anticoccidial agent.

54. Cancel.

55. Cancel.